Cargando…
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
Immunotherapy has shown great promise in the field of oncology, and recent clinical trials have illustrated that immune checkpoint blockade (ICB) is safe and effective at treating a range of tumor types. Cervical cancer (CC) is the fourth most common malignancy in women. However, first-line treatmen...
Autores principales: | Song, Zhuo, Zou, Kun, Zou, Lijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832370/ https://www.ncbi.nlm.nih.gov/pubmed/36644634 http://dx.doi.org/10.3389/fonc.2022.1045481 |
Ejemplares similares
-
Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022) -
The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer
por: Yazici, Gozde, et al.
Publicado: (2018) -
A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
por: Bila, Michel, et al.
Publicado: (2022) -
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
por: Chen, Ruifeng, et al.
Publicado: (2022) -
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)